1. Latest News
  2. Submit Press Release

Identifying and removing T cell epitopes in immunotoxins

SMi is proud to announce that expert Ronit Mazor will be presenting about her study on “Identifying and removing T cell epitopes in immunotoxins” at the inaugural Immunogenicity Conference

CENTRAL LONDON, U.K. - April 9, 2014 - PRLog -- Ronit Mazor , Research Fellow , National Cancer Institute N I H isconducting a study at the National Cancer Institute, National Institutes of Health about “Identification and Elimination of T-cell Epitopes in a Recombinant Immunotoxin Based on Pseudomonas Exotoxin A”.

"My project was to try to identify and eliminate what’s called epitopes, those parts of the bacterial portion that alarms the immune system.  They’re called T-cell epitopes.  T-cells are lymphocytes in our body that can recognize pathogens.  So that’s the work we’ve been doing, trying to identify and eliminate the T-cell epitope exotoxin A.” – by Ronit Mazor, 23rd January 2014, http://historyatnih.tumblr.com/post/74276591608/ronit-mazor-nci-identification-and-elimination (http://historyatnih.tumblr.com/post/74276591608/ronit-mazor-nci-identification-and-elimination)

Ronit Mazor will be presenting about her study at the inaugural Immunogenicity Conference taking place in London on the 14th and 15th July 2014. The presentation “Identifying and removing t cell epitopes in immunotoxins” will focus on:

• Immunotoxins are therapeutic proteins that are used to treat cancer. Immunogenicity is their main stumbling block in the clinic

• Assessing comprehensive experimental methods to identify and eliminate the T cell epitopes in the immunotoxin

• Designing a new immunotoxin that has significantly diminished T cell immunogenicity and yet an excellent anti-tumor effect

This conference will also feature a presentation from Key Opinion Leader David Scott, Professor and Vice Chair for Research, Uniformed Services University of Health Science about “Novel methods to induce tolerance for adverse immune Reactions

• Immune tolerance mechanisms versus reducing immunogenicity

• Application of B cell presentation for tolerance

• Fc fusion proteins and the role of IgG epitopes

• Application of specific T regulatory cells to control immune responses

For more information about the agenda and the speakers please visit http://www.smi-online.co.uk/immuno53.asp or contact Fateja Begum on +44 (0) 20 7827 6184 or email fbegum@smi-online.co.uk

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries.

We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries.

For more information, please visit www.smi-online.co.uk

SMi Group

--- End ---

Click to Share

Contact Email:
***@smi-online.co.uk Email Verified
Source:SMi Group
Location:Central London - London, Greater - United Kingdom
Industry:Event, Science
Tags:Immunogenicity, Immunotoxin, Antibodies, Immunology
Verified Account Email Address
Verified Account Phone Number

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “


Like PRLog?
Click to Share